Navigation Links
The GreeneChip- First Tool to Provide Differential Diagnosis of Infectious Diseases

The GreeneChip System is a new tool developed by researchers at Greene Infectious Disease Laboratory at Columbia University Mailman School of Public Health// and their colleagues in the WHO Global Laboratory Network.

The GreeneChip is the first tool to provide comprehensive, differential diagnosis of infectious diseases, including those caused by viruses, bacteria, fungi, or parasites. In addition, it is the first tool that can be used on a wide variety of samples, including tissue, blood, urine, and stool, allowing for the rapid identification of pathogens in a variety of laboratory and clinical settings.

The GreeneChip system and its application in an outbreak investigation when other methods failed to implicate a microorganism in a fatal hemorrhagic fever case is described in the January 2007 issue of the CDC's Emerging Infectious Diseases (online December 6 at www.cdc.gov/EID/13/1/06-0837.htm).

Globalization of travel and trade brings new infectious agents into new contexts. It is increasingly important to be prepared for the unexpected. "Because clinical syndromes are rarely specific for single pathogens, methods that simultaneously screen for multiple agents are important, particularly when early accurate diagnosis can alter treatment or assist in containment of an outbreak," stated W. Ian Lipkin, MD, director of the Greene Infectious Disease Laboratory at the Mailman School's Department of Epidemiology. He added, "To address the challenges of emerging infectious diseases and biodefense, public health practioners and diagnosticians need a comprehensive set of tools for pathogen surveillance and detection."

GreeneChip features include a comprehensive microbial sequence database that integrates previously distinct reserves of information about pathogens-for every entry of a pathogen and its properties, the GreeneChip contains a correlate of its genetic makeup. GreeneChip performance was initially tested by using s amples obtained from patients with respiratory disease, hemorrhagic fever, tuberculosis, and urinary tract infections. In all cases, GreeneChip analysis detected an agent that was consistent with the diagnosis obtained by more traditional and slower methods, such as culture or polymerase chain reaction (PCR).

In addition, the GreeneChip was used in the analysis of an unknown sample from a patient with a viral hemorrhagic fever (VHF)-like syndrome. Within six to eight days of infection, Marburg virus causes an acute febrile illness that frequently progresses to liver failure, delirium, shock, and hemorrhage. From October 2004 through July 2005, a Marburg outbreak in Angola resulted in 252 cases of hemorrhagic fever, with 90% of the cases fatal. Although most of the cases were confirmed through PCR as caused by Marburg virus, some were not.

During this outbreak, a healthcare worker from a nongovernmental organization had acute fever and liver failure that culminated in death within one week. PCR assays of RNA extracted from blood showed no evidence of Marburg infection. The same RNA was processed for panviral analysis with the GreeneChip. Still nothing was detected. The RNA was then tested with the GreeneChip for parasites. Analysis identified a Plasmodium (the species of parasite that causes human malaria). Chart review showed that the patient had recently arrived in Angola from a country where malaria was not endemic and that he had not taken malaria prophylaxis. Had the GreeneChip been available in the field to confirm the correct pathogen, the patient could have been treated for malaria.

Differential diagnosis of hemorrhagic fevers poses challenges for clinical medicine and public health. Syndromes associated with agents are not distinctive, particularly early in the course of disease. In some instances, including the case presented above, more than one agent may be endemic in the region with an outbreak. Outbreaks caused by different agents may also overlap in time and geography.

"We are very excited to work with the WHO to make an impact in managing disease outbreaks globally-especially in regions of the world where resources are scarce," stated Thomas Briese, PhD, associate director of the Greene Laboratory.

Implicit in globalization is the risk of known or new agents that appear in novel contexts. In 1996 a presumptive diagnosis of Ebola viral hemorrhagic fever in two children who had recently returned to New York City from West Africa resulted in closing a hospital emergency room. For example, one of the children died of cardiac failure caused by plasmodium falciparum (malaria). Therapeutic options for treatment of VHF are limited; however, rapid isolation if infected persons is critical to curb contagion. In contrast, human-to-human transmission is not a primary concern with malaria and early, specific therapy can have a profound effect on illness and death. The GreeneChip provides unprecedented opportunities for unbiased pathogen discovery and reduction of illness and death caused by infectious disease.

Source-Eurekalert
PRI
'"/>




Related medicine news :

1. First Vaccine Designed for Africa Cleared for Testing in Humans
2. Ajanta Launches Worlds First Once-A-Day Nimesulide Oral Formulation
3. First human clone is near
4. First Artificial Heart patient has Major setback
5. First head-to-head trials of once weekly Fosamax and Actonel therapies
6. WHO Declares Vietnam First Country to Control SARS
7. Russia Reports First SARS Case
8. Hope for First New Melanoma Treatment in Decades
9. First global SARS meet opens
10. Stanford Medical Center Implements The First Virtual Cardiac Ultrasound
11. Hyderabad To Have Asia’s First Catheter Making Uni
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:12/2/2016)... ... , ... The annual time frame to change Medicare health and prescription drug ... 7th. Currently-enrolled Medicare beneficiaries who are looking to switch from their current plan to ... make changes during this period order for their new policy to go into effect ...
(Date:12/2/2016)... ... December 02, 2016 , ... ... of two ostomy patients, standing as living proof that attitude and determination can ... diseases and issues that spike around the holidays. This campaign will offer patients ...
(Date:12/2/2016)... , ... December 02, 2016 , ... ... of "Cardiovascular Health" in USA Today, which covers the innovative treatments, therapeutic technologies, ... while maintaining fulfilling lives. “We are prolonging life 6 years in the last ...
(Date:12/2/2016)... ... December 02, 2016 , ... Universal Medical Systems, Inc. ... the first company to offer robotic imaging to veterinary medicine is sponsoring the ... 941 for the American Association of Equine Practitioners 62nd Annual Convention from December ...
(Date:12/2/2016)... Texas (PRWEB) , ... December 02, 2016 , ... Yisrayl ... that delves into how this current generation fits into Bible Prophecy. Yisrayl says this ... various facts pointing to this conclusion, showing how the details line up exactly with ...
Breaking Medicine News(10 mins):
(Date:12/2/2016)... 2, 2016  The Addiction Treatment Advisory Group ... Managed Care Pharmacy (AMCP), has released detailed findings ... the opioid addiction crisis, including through improved access ... ATAG,s newly released paper, "The Role of ... addresses many issues around gaps and barriers to ...
(Date:12/2/2016)... , Dec. 2, 2016  Maxor National Pharmacy Services, LLC ... Pharmaceutical Specialties, Inc. ("PSI").  The combination of Texas ... Georgia -based PSI bring together both company,s clinical expertise ... and payers an industry-leading specialty pharmacy. About Maxor ... , , ...
(Date:12/2/2016)... R.I. , Dec. 2, 2016 CVS ... its annual Analyst Day in New York City on Thursday, December 15, ... CVS Health leadership team will provide an in-depth review ... enhance shareholder value. The company will also discuss 2017 ... and video webcast of the event will be broadcast ...
Breaking Medicine Technology: